-continued



and

13. The molecule of claim **1** wherein said molecule is an inhibitor of a mammalian BRAG2.

14. An in vitro or in cellulo method for inhibiting a mammalian BRAG2, said method comprising contacting the mammalian BRAG2 with a BRAG2 inhibitor according to claim **7**.

15. A pharmaceutical composition comprising at least one molecule according to claim **1**, said composition comprising one or more excipients and optionally one other pharmaceutically active ingredient.

16-19. (canceled)

20. A method of therapeutic treatment, said method comprising administering to a mammal in need thereof an effective amount of at least one molecule according to claim **1**.

21. The method of claim **20**, wherein said method is for treating a disease presenting a deregulated expression of BRAG2.

22. The method according to claim **20**, wherein said method is for treating a disease is selected from the group consisting of a cancer, angiogenesis, diabetic retinopathy, or non-syndromic intellectual disability.

23. The method of claim **20**, wherein said method is for treating a disease selected from the group consisting of a cancer, in particular an invasive cancer, a cancer with metastasis, a cancer resistant to an EGFR and/or ErbB2 modulator, angiogenesis, diabetic retinopathy, non-syndromic intellectual disability.

24. The method of claim **20**, wherein said molecule is an inhibitor having one or more protein-membrane interactions and inhibiting a mammal BRAG2, and wherein said method is for the treatment of a cancer.

25. The molecule according to claim **3**, wherein
the alkyl is methyl (Me) or ethyl (Et); and/or
the O-alkyl is OMe or OEt; and/or
the alkyne, is —CCH; and/or
the O-alkyne is —OCH2-CCH.

26. The molecule according to claim **4**, wherein
the alkyl is methyl (Me) or ethyl (Et); and/or
the O-alkyl, is OMe or OEt; and/or
the alkyne is —CCH; and/or
the O-alkyne is —OCH2-CCH.

* * * * *